LOXL2 and breast carcinoma: As aberrant expression and activity of LOXL2 have been reported in various cancer types [7–9], we checked the levels of LOXL2 and H3K4ox in several breast cancer cell lines representing different subtypes: luminal A, in the T-47D and MCF-7 cell lines (ER+/HER2–/PR+/–); luminal B, in the BT-474 cell line (ER+/HER2+/PR+/–); and basal TNBC, in the human MDA-MB-231 (ER–/HER2–/PR–) cell line [25].